We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$14.9M
1-Year Est. Return
38.76%
This Fund
S&P 500
This Quarter
Est. Return
-5.18%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$2.76B
AUM Growth
-$525M
(-16%)
Cap. Flow
-$439M
Cap. Flow
% of AUM
-15.9%
Top 10 Holdings %
Top 10 Hldgs %
38.29%
Holding
343
New
69
Increased
54
Reduced
100
Closed
111
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VRAY
ViewRay, Inc.
VRAY
|
+$17.9M |
| 2 |
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
|
+$17.3M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$14.1M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$14M |
| 5 |
CUTR
Cutera, Inc.
CUTR
|
+$12.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Seer Inc
SEER
|
+$24.7M |
| 2 |
MAPS
WM TECHNOLOGY INC A
MAPS
|
+$23.4M |
| 3 |
LivaNova
LIVN
|
+$20.2M |
| 4 |
Glaukos
GKOS
|
+$17.5M |
| 5 |
Cooper Companies
COO
|
+$16.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 29.75% |
| 2 | Consumer Staples | 0.58% |
| 3 | Financials | 0.5% |
| 4 | Consumer Discretionary | 0.42% |
| 5 | Industrials | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
IMGN
126
PUT
DELISTED
Immunogen Inc
IMGN
| $3.6M | 0.13% |
484,600
-166,100
| -26% | -$1.03M |
|
127
Travere Therapeutics
TVTX
$5.86B
| $3.41M | 0.12% |
109,925
+56,135
| +104% | +$1.58M |
|
|
AXNX
128
PUT
DELISTED
Axonics, Inc. Common Stock
AXNX
| $3.31M | 0.12% |
+59,100
| New | +$3.61M |
|
129
CALL
Aurinia Pharmaceuticals
AUPH
$2.06B
| $3.25M | 0.12% |
142,100
-57,900
| -29% | -$1.37M |
|
130
PUT
Universal Health Services
UHS
$10.2B
| $3.2M | 0.12% |
24,700
-165,300
| -87% | -$21.2M |
|
131
PUT
Organogenesis Holdings
ORGO
$233M
| $3.19M | 0.12% |
345,000
+60,500
| +21% | +$643K |
|
|
APEN
132
DELISTED
Apollo Endosurgery, Inc.
APEN
| $3.16M | 0.11% |
+374,657
| New | +$3.27M |
|
|
BLU
133
DELISTED
BELLUS Health Inc.
BLU
| $3.12M | 0.11% |
387,797
+52,992
| +16% | +$352K |
|
134
Rapid Micro Biosystems
RPID
$84.8M
| $2.95M | 0.11% |
276,871
-55,265
| -17% | -$863K |
|
135
Arcutis Biotherapeutics
ARQT
$3.3B
| $2.88M | 0.1% |
138,663
+26,339
| +23% | +$524K |
|
136
PUT
Fate Therapeutics
FATE
$317M
| $2.84M | 0.1% |
48,500
-1,500
| -3% | -$85K |
|
137
CALL
Bausch Health
BHC
$2.32B
| $2.72M | 0.1% |
98,600
-331,400
| -77% | -$8.87M |
|
138
BioNTech
BNTX
$23.3B
| $2.54M | 0.09% |
+9,857
| New | +$2.7M |
|
139
PUT
Kodiak Sciences
KOD
$2.72B
| $2.47M | 0.09% |
+29,100
| New | +$2.96M |
|
140
PUT
AdaptHealth
AHCO
$770M
| $2.41M | 0.09% |
+98,600
| New | +$2.31M |
|
|
IMGN
141
CALL
DELISTED
Immunogen Inc
IMGN
| $2.41M | 0.09% |
325,000
-772,500
| -70% | -$4.8M |
|
142
Adicet Bio
ACET
$77.3M
| $2.39M | 0.09% |
+8,551
| New | +$1.47M |
|
143
United Therapeutics
UTHR
$21.9B
| $2.33M | 0.08% |
10,758
+2,171
| +25% | +$426K |
|
|
ARNA
144
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $2.26M | 0.08% |
24,361
+4,361
| +22% | +$287K |
|
|
LYRA
145
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $2.25M | 0.08% |
10,345
-323
| -3% | -$104K |
|
146
Viridian Therapeutics
VRDN
$2.59B
| $2.07M | 0.08% |
104,860
+46,764
| +80% | +$871K |
|
147
Phathom Pharmaceuticals
PHAT
$742M
| $2M | 0.07% |
101,728
+69,153
| +212% | +$1.63M |
|
148
CALL
Guardant Health
GH
$22.2B
| $2M | 0.07% |
+20,000
| New | +$2.07M |
|
|
MRUS
149
DELISTED
Merus
MRUS
| $1.86M | 0.07% |
+58,660
| New | +$1.66M |
|
150
Merck
MRK
$328B
| $1.86M | 0.07% |
24,246
-60,754
| -71% | -$4.84M |
|
Similar funds
BCA
RC
DOFI
SCI
LPC
GBCP
SCTC
M
Pura Vida Investments's Q4 2021 Portfolio in Review
As of Q4 2021, Pura Vida Investments held 343 positions worth $2.76B, down 16% from $3.29B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Pura Vida Investments withdrew a net $439M in Q4 2021, closing 111 positions and reducing 100 holdings. Its most notable exit was Seer Inc, an estimated $24.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 33% a quarter earlier, followed by Consumer Staples and Financials.
Against the trend, Pura Vida Investments opened a new position in BioMarin Pharmaceuticals worth $15M.
- Pura Vida Investments's largest Q4 2021 buy was BioMarin Pharmaceuticals: 170,210 shares worth $15M.
- Pura Vida Investments added most to ViewRay, Inc. in Q4 2021, an estimated $17.9M increase.
- Pura Vida Investments's biggest Q4 2021 reduction was LivaNova, cutting an estimated $20.2M.
- Pura Vida Investments fully exited Seer Inc in Q4 2021, selling an estimated $24.7M.
- Pura Vida Investments's ten largest holdings make up 38% of its $2.76B portfolio in Q4 2021.
- Pura Vida Investments opened 69 new positions and closed 111 in Q4 2021.
- Pura Vida Investments's portfolio value fell 16% quarter-over-quarter to $2.76B.
Based on Pura Vida Investments's 13F filing for Q4 2021, filed 14 Feb 2022.